Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887969332> ?p ?o ?g. }
- W2887969332 endingPage "664" @default.
- W2887969332 startingPage "654" @default.
- W2887969332 abstract "Abstract Objectives To present the Central European Myeloproliferative Neoplasm Organisation (CEMPO) treatment recommendations for polycythaemia vera (PV). Methods During meetings held from 2015 through 2017, CEMPO discussed PV and its treatment and recent data. Results PV is associated with increased risks of thrombosis/thrombo‐haemorrhagic complications, fibrotic progression and leukaemic transformation. Presence of Janus kinase (JAK)‐2 gene mutations is a diagnostic marker and standard diagnostic criterion. World Health Organization 2016 diagnostic criteria for PV, focusing on haemoglobin levels and bone marrow morphology, are mandatory. PV therapy aims at managing long‐term risks of vascular complications and progression towards transformation to acute myeloid leukaemia and myelodysplastic syndrome. Risk stratification for thrombotic complications guides therapeutic decisions. Low‐risk patients are treated first line with low‐dose aspirin and phlebotomy. Cytoreduction is considered for low‐risk (phlebotomy intolerance, severe/progressive symptoms, cardiovascular risk factors) and high‐risk patients. Hydroxyurea is suspected of leukaemogenic potential. IFN‐α has demonstrated efficacy in many clinical trials; its pegylated form is best tolerated, enabling less frequent administration than standard interferon. Ropeginterferon alfa‐2b has been shown to be more efficacious than hydroxyurea. JAK 1/ JAK 2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients. Conclusions Greater understanding of PV is serving as a platform for new therapy development and treatment response predictors." @default.
- W2887969332 created "2018-08-22" @default.
- W2887969332 creator A5004340496 @default.
- W2887969332 creator A5006360930 @default.
- W2887969332 creator A5006834567 @default.
- W2887969332 creator A5008646185 @default.
- W2887969332 creator A5011170839 @default.
- W2887969332 creator A5014284178 @default.
- W2887969332 creator A5029935496 @default.
- W2887969332 creator A5030347392 @default.
- W2887969332 creator A5032138074 @default.
- W2887969332 creator A5033444900 @default.
- W2887969332 creator A5049331182 @default.
- W2887969332 creator A5062322697 @default.
- W2887969332 creator A5067366555 @default.
- W2887969332 creator A5071046554 @default.
- W2887969332 creator A5072515292 @default.
- W2887969332 creator A5074486986 @default.
- W2887969332 creator A5076944328 @default.
- W2887969332 creator A5085056878 @default.
- W2887969332 creator A5091155004 @default.
- W2887969332 date "2018-09-11" @default.
- W2887969332 modified "2023-10-01" @default.
- W2887969332 title "Recommendations for the diagnosis and treatment of patients with polycythaemia vera" @default.
- W2887969332 cites W1446966563 @default.
- W2887969332 cites W1547986283 @default.
- W2887969332 cites W1644692312 @default.
- W2887969332 cites W166660488 @default.
- W2887969332 cites W1821109160 @default.
- W2887969332 cites W1825604416 @default.
- W2887969332 cites W1924341697 @default.
- W2887969332 cites W1950034597 @default.
- W2887969332 cites W1959044271 @default.
- W2887969332 cites W1964863089 @default.
- W2887969332 cites W1967376890 @default.
- W2887969332 cites W1975135941 @default.
- W2887969332 cites W1979293726 @default.
- W2887969332 cites W1979832242 @default.
- W2887969332 cites W1980568348 @default.
- W2887969332 cites W1982989509 @default.
- W2887969332 cites W1983892731 @default.
- W2887969332 cites W1984285934 @default.
- W2887969332 cites W1984960437 @default.
- W2887969332 cites W1988019098 @default.
- W2887969332 cites W1990387953 @default.
- W2887969332 cites W1996502308 @default.
- W2887969332 cites W1998626781 @default.
- W2887969332 cites W2009267659 @default.
- W2887969332 cites W2011253478 @default.
- W2887969332 cites W2012686883 @default.
- W2887969332 cites W2012793659 @default.
- W2887969332 cites W2019635573 @default.
- W2887969332 cites W2025001402 @default.
- W2887969332 cites W2030868349 @default.
- W2887969332 cites W2033914091 @default.
- W2887969332 cites W2045494967 @default.
- W2887969332 cites W2054851157 @default.
- W2887969332 cites W2057129764 @default.
- W2887969332 cites W2063731736 @default.
- W2887969332 cites W2063756127 @default.
- W2887969332 cites W2064690570 @default.
- W2887969332 cites W2064812526 @default.
- W2887969332 cites W2066465348 @default.
- W2887969332 cites W2068093121 @default.
- W2887969332 cites W2068302080 @default.
- W2887969332 cites W2072881492 @default.
- W2887969332 cites W2073530790 @default.
- W2887969332 cites W2076488817 @default.
- W2887969332 cites W2076733126 @default.
- W2887969332 cites W2078182058 @default.
- W2887969332 cites W2082727246 @default.
- W2887969332 cites W2085128863 @default.
- W2887969332 cites W2086511628 @default.
- W2887969332 cites W2089993696 @default.
- W2887969332 cites W2094343412 @default.
- W2887969332 cites W2094456737 @default.
- W2887969332 cites W2097922857 @default.
- W2887969332 cites W2098215007 @default.
- W2887969332 cites W2099165047 @default.
- W2887969332 cites W2101502003 @default.
- W2887969332 cites W2102404297 @default.
- W2887969332 cites W2107398329 @default.
- W2887969332 cites W2112316414 @default.
- W2887969332 cites W2113792044 @default.
- W2887969332 cites W2114995805 @default.
- W2887969332 cites W2119941797 @default.
- W2887969332 cites W2122395736 @default.
- W2887969332 cites W2123587611 @default.
- W2887969332 cites W2133633030 @default.
- W2887969332 cites W2137981147 @default.
- W2887969332 cites W2147370660 @default.
- W2887969332 cites W2149373649 @default.
- W2887969332 cites W2151757571 @default.
- W2887969332 cites W2158669800 @default.
- W2887969332 cites W2159962994 @default.
- W2887969332 cites W2162189197 @default.
- W2887969332 cites W2163831007 @default.
- W2887969332 cites W2175257806 @default.